Filing Overview
On June 13, 2023, Blue Water Biotech, Inc. entered into an Asset Purchase Agreement to acquire six FDA-approved pharmaceutical assets from WraSer, LLC and Xspire Pharma, LLC, subsidiaries of Legacy-Xspire Holdings, LLC. The filing identifies the registrant as Blue Water Biotech, Inc.; this differs from the requested company name, Onconetix, Inc.
Business Context and Transaction Terms
- The assets cover cardiology, otic infections, hypertension, and pain management.
- The portfolio includes ZONTIVITY, indicated to reduce thrombotic cardiovascular events in certain patients with a history of myocardial infarction or peripheral arterial disease.
- Consideration consists of $3.5 million in cash at signing, $4.5 million in cash at closing, 1.0 million shares of common stock issued at closing, and $500,000 in cash one year after closing.
- The stated cash consideration totals $8.5 million, excluding the value of the common-stock issuance.
- Closing is subject to customary conditions, including receipt of audited 2021 and 2022 financial statements of the sellers and parent company.
Financial Metrics and Liquidity
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or operating results for the acquired assets or the company.
- Between signing and closing, the company will manage and fund operation of the assets and receive any related profits under a Management Services Agreement.
- The filing does not state how the cash payments will be financed or their expected effect on the company’s liquidity.
Material Changes and Securities Issuance
- The transaction represents a material expansion into FDA-approved commercial pharmaceutical products.
- The 1.0 million shares will be issued without registration under Section 4(a)(2) of the Securities Act.
- Within 90 days after closing, the company expects to use best efforts to file a Form S-3 registration statement for resale of the shares.
- The filing does not provide a pro forma ownership percentage or quantify dilution to existing shareholders.
Outlook, Risks, and Unusual Items
- The acquisition had not necessarily closed as of the filing date; completion remained subject to closing conditions.
- The company will assume liabilities associated with the assets arising on or after the closing date.
- Execution depends on the sellers delivering acceptable audited financial statements and satisfying other customary conditions.
- The parties provided customary representations, warranties, covenants, and indemnification provisions, subject to stated exceptions and limitations.
- Required financial statements of the acquired business and pro forma financial information were expected to be filed by amendment, if required, within 71 days after the Form 8-K filing deadline.
- No formal financial guidance or quantified outlook was provided.
Key Facts for Investors to Verify
- Whether and when the acquisition formally closed.
- The acquired assets’ audited historical revenue, profitability, cash flow, and liabilities.
- The company’s available cash and financing sources for the $8.5 million cash consideration and interim operating funding.
- The final number of shares outstanding and dilution from the 1.0 million-share issuance.
- Any subsequent filing containing required financial statements and pro forma financial information.
- The regulatory, commercial, supply, and market status of ZONTIVITY and the other acquired products.